Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH001 + Envafolimab +/- Doxorubicin in Advanced Sarcoma
NCT05448820Phase 2Active, not recruiting
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of YH001 in sarcoma (8 arms), sponsored by TRACON Pharmaceuticals, Inc. Primary endpoints: Recommended Phase 2 Dose of YH001 in combination with Envafolimab at 8 months, Recommended Phase 2 Dose of YH001 in combination with Envafolimab with Doxorubicin at 8 months and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
YH001
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT05448820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05448820.